OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast Cancer

February 13th 2024

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

February 13th 2024

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Dr Wainberg on the FDA Approval of NALIRIFOX in mPDAC

February 13th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

February 13th 2024

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Dr Feldman on the Background of the TRANSCEND CLL 004 Trial in CLL/SLL

February 13th 2024

Tatyana Feldman, MD, discusses the launch of the TRANSCEND CLL 004 trial in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr Zonder on Unmet Needs to be Addressed in Multiple Myeloma

February 13th 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

Dr Galsky on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 12th 2024

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Dr Garmezy on Choosing an IO/TKI Treatment Regimen in ccRCC

February 10th 2024

Benjamin Garmezy, MD, discusses in when to choose an IO/TKI regimen for the treatment of patients with ccRCC.

Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian Cancer

February 10th 2024

Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.

Dr Advani on Advancements in the Treatment of TNBC

February 10th 2024

Pooja Advani, MBBS, MD, discusses key advancements that have occurred for the treatment of patients with triple-negative breast cancer.

Dr Dima on the Mechanism of Action of Teclistamab in Relapsed/Refractory Multiple Myeloma

February 9th 2024

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

February 9th 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

Dr Bishop on the Utility of Obe-Cel in Relapsed/Refractory B-ALL

February 8th 2024

Michael R. Bishop, MD, discusses the FELIX study, highlighting the safety of obe-cel in B-cell acute lymphoblastic leukemia.

Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma

February 8th 2024

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

Dr Grivas on Updated Data in the Treatment of Metastatic/Unresectable Urothelial Carcinoma

February 8th 2024

Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.

Dr Takvorian on the Evolution of PARP Inhibitors in Prostate Cancer

February 8th 2024

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.

Dr Pearse on Efforts to Elucidate the Optimal Sequencing of BTK Inhibitors in MCL

February 8th 2024

William B. Pearse, MD, discusses unanswered questions regarding the sequencing of pirtobrutinib and other BTK inhibitors in mantle cell lymphoma.

Dr Coombs on Notable BTK Inhibitor Combination Studies in CLL

February 8th 2024

Callie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.

Dr Siegel on the Rationale for Investigating KID in Multiple Myeloma

February 8th 2024

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Dr Mikhael on the Utility of Isa-KRd in Newly Diagnosed Multiple Myeloma

February 7th 2024

Joseph Mikhael, MD, discusses the utility of isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.